trial · primary record
Remibrutinib oral treatment
Relapsing Multiple Sclerosis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 400 |
| Primary completion | 2031-06-25 |
| Primary endpoint | Annualized rate of new or enlarging T2 lesions_Core Part |
| Registry ID | NCT06846281 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:38.282Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06846281
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.